CVS Health (NYSE:CVS) Director Larry Robbins Sells 370,462 Shares of Stock

CVS Health Corporation (NYSE:CVS) Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Larry Robbins also recently made the following trade(s):

• On Wednesday, May 20th, Larry Robbins sold 1,018,000 shares of CVS Health stock. The stock was sold at an average price of $93.82, for a total value of $95,508,760.00.
• On Tuesday, May 19th, Larry Robbins sold 1,983,538 shares of CVS Health stock. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10.

CVS Health Stock Up 0.1%

NYSE CVS opened at $93.35 on Friday. The stock has a market cap of $119.11 billion, a PE ratio of 41.12, a P/E/G ratio of 0.91 and a beta of 0.60. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $98.43. The business has a 50 day moving average price of $80.03 and a two-hundred day moving average price of $78.98. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio is 117.18%.

Institutional Investors Weigh In On CVS Health

Several institutional investors and hedge funds have recently made changes to their positions in CVS. Caitong International Asset Management Co. Ltd raised its position in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Swiss RE Ltd. acquired a new stake in shares of CVS Health during the 4th quarter valued at approximately $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health during the 4th quarter valued at approximately $28,000. Global Trust Asset Management LLC raised its position in shares of CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after acquiring an additional 300 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health during the 4th quarter valued at approximately $28,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Glenview Capital said its CVS position has produced about an 80% total return since May 2024, signaling continued investor confidence in CVS’s long-term turnaround and helping reinforce the bullish case. Glenview Capital Issues Statement on CVS Health
• Positive Sentiment: Recent company-news items highlighting community programs, military support, and affordable senior housing may modestly support CVS’s brand and long-term ESG narrative, though they are unlikely to move the stock as much as the legal headlines. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Neutral Sentiment: Director Larry Robbins disclosed large stock sales over several days, including a roughly $187 million sale and other sizable transactions, but he still retains a large stake; the filings may be read as routine diversification rather than a full exit. SEC Form 4 filing
• Negative Sentiment: Hospitals allege CVS and its affiliates secretly captured 340B savings, which could lead to litigation costs, potential settlements, and tighter oversight of CVS’s pharmacy-benefit operations. Hospitals allege contracted CVS Health subsidiaries pocketed their 340B savings
• Negative Sentiment: Separate reports from the University of Michigan and University of Kansas hospital systems expanded the dispute and added to concerns that CVS could face multiple 340B-related lawsuits and rising legal exposure. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment

Wall Street Analysts Forecast Growth

CVS has been the subject of several research analyst reports. Morgan Stanley increased their target price on CVS Health from $93.00 to $106.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. HSBC increased their target price on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Tuesday, May 5th. Bank of America reduced their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Finally, Mizuho upped their price target on CVS Health from $102.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.68.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.